E-mail Address
Forgot your password? Click here to reset it

Request an Account


Arisaph Pharmaceuticals

September 29, 2014
Arisaph Pharmaceuticals Awarded Supplemental Phase I And Phase II STTR Grants To Develop Oncology Drug Candidates

Edgemont Pharmaceuticals

December 3, 2014
IntelGenx Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)


December 22, 2014
ImmusanT Raises $12 Million in Series B Financing

November 20, 2014
Cambridge company recognized for potential Celiac-curing vaccine

November 19, 2014
ImmusanT’s Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa’s Top 10 Autoimmune/Anti-Inflammatory Projects to Watch

November 6, 2014
Journal of Autoimmunity Publishes Research Supporting Safety of Oats in the Celiac Diet

April 29, 2014
New Research Published in Nature Structural and Molecular Biology Shows How Wheat Activates the Immune Response to Gluten in Celiac Disease

March 11, 2014
Get a Shot, Have Some Bread: ImmusanT’s Plan For a Celiac Vaccine

January 6, 2014
New Test in Celiac Disease Provides Powerful Tool for Diagnosis and Immune Monitoring

Melinta Therapeutics

February 9, 2015
Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital

January 8, 2015
Melinta Therapeutics and Eurofarma Laboratórios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil

January 7, 2015
Melinta Therapeutics’ Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI

September 8, 2014
Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae

September 6, 2014
Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens

September 6, 2014
Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program

September 4, 2014
Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting

August 14, 2014
Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy

August 11, 2014
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration

June 17, 2014
Melinta Therapeutics to Present at Annual JMP Securities Healthcare Conference

May 5, 2014
Melinta Therapeutics’ Phase 3 Study of I.V. and Oral Delafloxacin has Begun Enrolling Patients with Acute Bacterial Skin and Skin Structure Infections

February 10, 2014
Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform

Pearl Therapeutics

June 10, 2013
Pearl Therapeutics to be Acquired by AstraZeneca for up to $1.15 Billion